Nadia A Nabulsi1, Ali Alobaidi1, Brian Talon1, Alemseged A Asfaw1, Jifang Zhou1, Lisa K Sharp1, Karen Sweiss2, Pritesh R Patel3, Naomi Y Ko4, Brian C-H Chiu5, Gregory S Calip6,7. 1. Department of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA. 2. Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA. 3. Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA. 4. Section of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA. 5. Department of Public Health Sciences, The University of Chicago, Chicago, IL, USA. 6. Department of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA. gcalip@uic.edu. 7. Division of Public Health Sciences, Epidemiology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. gcalip@uic.edu.
Abstract
PURPOSE: Patient-reported outcomes such as self-reported health (SRH) are important in understanding quality cancer care, yet little is known about links between SRH and outcomes in older patients with multiple myeloma (MM). We evaluated associations between SRH and mortality among older patients with MM. METHODS: We analyzed a retrospective cohort of patients ages ≥ 65 years diagnosed with first primary MM using the Surveillance, Epidemiology, and End Results (SEER)-Medicare Health Outcomes Survey (MHOS) data resource. Pre-diagnosis SRH was grouped as high (excellent/very good/good) or low (fair/poor). We used Cox proportional hazards models to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI) for associations between SRH and all-cause and MM-specific mortality. RESULTS: Of 521 MM patients with mean (SD) age at diagnosis of 76.8 (6.1) years, 32% reported low SRH. In multivariable analyses, low SRH was suggestive of modest increased risks of all-cause mortality (HR 1.32, 95% CI 1.02-1.71) and MM-specific mortality (HR 1.22, 95% CI 0.87-1.70) compared to high SRH. CONCLUSION: Findings suggest that low pre-diagnosis SRH is highly prevalent among older patients with MM and is associated with modestly increased all-cause mortality. Additional research is needed to address quality of life and modifiable factors that may accompany poor SRH in older patients with MM.
PURPOSE:Patient-reported outcomes such as self-reported health (SRH) are important in understanding quality cancer care, yet little is known about links between SRH and outcomes in older patients with multiple myeloma (MM). We evaluated associations between SRH and mortality among older patients with MM. METHODS: We analyzed a retrospective cohort of patients ages ≥ 65 years diagnosed with first primary MM using the Surveillance, Epidemiology, and End Results (SEER)-Medicare Health Outcomes Survey (MHOS) data resource. Pre-diagnosis SRH was grouped as high (excellent/very good/good) or low (fair/poor). We used Cox proportional hazards models to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI) for associations between SRH and all-cause and MM-specific mortality. RESULTS: Of 521 MM patients with mean (SD) age at diagnosis of 76.8 (6.1) years, 32% reported low SRH. In multivariable analyses, low SRH was suggestive of modest increased risks of all-cause mortality (HR 1.32, 95% CI 1.02-1.71) and MM-specific mortality (HR 1.22, 95% CI 0.87-1.70) compared to high SRH. CONCLUSION: Findings suggest that low pre-diagnosis SRH is highly prevalent among older patients with MM and is associated with modestly increased all-cause mortality. Additional research is needed to address quality of life and modifiable factors that may accompany poor SRH in older patients with MM.
Authors: Richard M Hoffman; Tatsuki Koyama; Peter C Albertsen; Michael J Barry; Timothy J Daskivich; Michael Goodman; Ann S Hamilton; Janet L Stanford; Antoinette M Stroup; Arnold L Potosky; David F Penson Journal: J Gen Intern Med Date: 2015-02-13 Impact factor: 5.128
Authors: Constantinos Koshiaris; Jason Oke; Lucy Abel; Brian D Nicholson; Karthik Ramasamy; Ann Van den Bruel Journal: BMJ Open Date: 2018-06-22 Impact factor: 2.692
Authors: Bernard Tawfik; Ellen Burgess; Mikaela Kosich; Shoshana Adler Jaffe; Dolores D Guest; Ursa Brown-Glaberman; V Shane Pankratz; Andrew Sussman Journal: Cancer Causes Control Date: 2022-07-13 Impact factor: 2.532
Authors: Nadia A Nabulsi; Khatija W Naing; Huiwen Deng; Jenilee Cueto; Alemseged A Asfaw; Colin C Hubbard; Jifang Zhou; Inyoung Lee; Debanjali Mitra; Gregory S Calip; Ernest H Law Journal: J Patient Exp Date: 2022-07-11
Authors: Evangelos Terpos; Joseph Mikhael; Roman Hajek; Ajai Chari; Sonja Zweegman; Hans C Lee; María-Victoria Mateos; Alessandra Larocca; Karthik Ramasamy; Martin Kaiser; Gordon Cook; Katja C Weisel; Caitlin L Costello; Jennifer Elliott; Antonio Palumbo; Saad Z Usmani Journal: Blood Cancer J Date: 2021-02-18 Impact factor: 11.037
Authors: Lisa D DiMartino; Justin Kirschner; George L Jackson; Michelle A Mollica; Lisa M Lines Journal: Cancer Causes Control Date: 2021-05-27 Impact factor: 2.532